Prostatic artery embolization is a minimally invasive procedure performed to treat symptoms of benign prostatic hyperplasia (BPH) by reducing blood flow to the prostate using tiny synthetic particles delivered via catheter from the groin area. It provides an alternative to medication and surgery, offering advantages like faster recovery time, lesser complications and cost effectiveness. The Global Prostatic Artery Embolization Market Size is estimated to be valued at US$ 270.72 Bn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The increasing prevalence of benign prostatic hyperplasia among the aging male population is a key factor fueling the growth of global prostatic artery embolization market over the forecast period. BPH is a very common medical condition among aging men and its prevalence increases with age. For instance, according to the data published by National Institute of Diabetes and Digestive and Kidney Diseases, around 50% of men in their 50s and up to 90% in their 70s or 80s have BPH symptoms. Prostatic artery embolization provides an effective minimally invasive treatment alternative to drug therapy and surgery for enlarged prostate symptoms caused by BPH. Other key trends behind the market growth include growing awareness about the benefits of prostatic artery embolization over conventional treatment options and technological advancements leading to improved procedural outcomes.

Segment Analysis:
The global prostatic artery embolization market is dominated by the Benign prostatic hyperplasia (BPH) segment. BPH is a common noncancerous enlargement of the prostate gland in men that causes urinary problems. BPH segment accounted for over 80% of the overall market share in 2024 as prostatic artery embolization procedure is minimally invasive and highly adopted alternative treatment for alleviating BPH symptoms. Prostate cancer segment is also expected to grow at a steady pace over the forecast period due to increasing cases of prostate cancer and demand for non-surgical effective treatments.

Key Takeaways:
The global prostatic artery embolization market is expected to witness high growth over the forecast period.

North America is projected to account for the largest market share owing to technological advancements, availability of skilled healthcare professionals and growing preference for minimally invasive procedures in the region. Furthermore, presence of key market players and favorable reimbursement policies are driving the prostatic artery embolization adoption in the US and Canada.

Key players operating in the prostatic artery embolization market are Ingersoll-Rand plc (Nexia), Vivint, Inc., Protection One Alarm Monitoring, Inc., The ADT Corporation, Telus Communications, Frontpoint Security Solutions, AT&T Inc., Johnson Controls, Inc., Comcast Corporation, Charter Communications (TWC), and CenturyLink, Inc. Ingersoll-Rand plc (Nexia) and Vivint, Inc. collectively accounted for over 30% of the global market share in 2024 owing to their robust product portfolios and widespread geographical presence across North America and Europe.

Get More Insights on This Topic: https://www.ukwebwire.com/prostatic-artery-embolization-market-trends-growth-and-regional-outlook-2023-2030/

Explore Related Report, Please Visit: https://masstamilan.tv/nasal-sprays-in-the-united-states-an-overview/